ArticlePLoS medicine2012
Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures.
Article in PLoS medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis.Intensive care medicine · 2013Pooled it
- Doctors' Conflict-of-Interest; What it Looks Like and What to do About it.International journal of social determinants of health and health services · 2026Article
- Retraction and correction of scientific articles due to conflicts of interest: a cross‑sectional analysis of the Retraction Watch database.Research integrity and peer review · 2026Article
- Article
- Relationship Between Declarations of Conflict of Interests and Reporting Positive Outcomes in Iranian Dental Journals.Science and engineering ethics · 2019Review
- Disclosures of Coca-Cola funding: transparent or opaque?Public health nutrition · 2018Article
- Conflicts of interest of editors of medical journals.PloS one · 2018Article
- Discordance of conflict of interest self-disclosure and the Centers of Medicare and Medicaid Services.The Journal of surgical research · 2017Observational
- Article
- The relationship between the physician and pharmaceutical industry: background ethics and regulation proposals.Croatian medical journal · 2016Article
- Conflicts of interest in research: looking out for number one means keeping the primary interest front and center.Current reviews in musculoskeletal medicine · 2015Article
- Conflict of interest reporting in dentistry meta-analyses: A systematic review.Journal of clinical and experimental dentistry · 2014Review
- [Not Available].The Canadian journal of hospital pharmacy · 2014Article
- Industry influence in evidence production.Journal of epidemiology and community health · 2013Article
- Article
- Conflict of interest disclosure in biomedical research: A review of current practices, biases, and the role of public registries in improving transparency.Research integrity and peer reviewArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLitigation documents reveal that pharmaceutical companies have paid physicians to promote off-label uses of their products through a number of different avenues. It is unknown whether physicians and scientists who have such conflicts of interest adequately disclose such relationships in the scientific publications they author. METHODS AND
findingsWe collected whistleblower complaints alleging illegal off-label marketing from the US Department of Justice and other publicly available sources (date range: 1996-2010). We identified physicians and scientists described in the complaints as having financial relationships with defendant manufacturers, then searched Medline for articles they authored in the subsequent three years. We assessed disclosures made in articles related to the off-label use in question, determined the frequency of adequate disclosure statements, and analyzed characteristics of the authors (specialty, author position) and articles (type, connection to off-label use, journal impact factor, citation count/year). We identified 39 conflicted individuals in whistleblower complaints. They published 404 articles related to the drugs at issue in the whistleblower complaints, only 62 (15%) of which contained an adequate disclosure statement. Most articles had no disclosure (43%) or did not mention the pharmaceutical company (40%). Adequate disclosure rates varied significantly by article type, with commentaries less likely to have adequate disclosure compared to articles reporting original studies or trials (adjusted odds ratio [OR] = 0.10, 95%CI = 0.02-0.67, p = 0.02). Over half of the authors (22/39, 56%) made no adequate disclosures in their articles. However, four of six authors with ≥ 25 articles disclosed in about one-third of articles (range: 10/36-8/25 [28%-32%]).
conclusionsOne in seven authors identified in whistleblower complaints as involved in off-label marketing activities adequately disclosed their conflict of interest in subsequent journal publications. This is a much lower rate of adequate disclosure than has been identified in previous studies. The non-disclosure patterns suggest shortcomings with authors and the rigor of journal practices. Please see later in the article for the Editors' Summary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.